Drugs / allogeneic fecal microbiota
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04203017 | Jun 2019 → Nov 2023 | multiple sclerosis | St. Petersburg State Pavlov Medical University | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04269850 | Sep 2019 → Nov 2024 | acute graft versus host disease | St. Petersburg State Pavlov Medical University | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogeneic fecal microbiota | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04203017 ↗ |
| Action | Restore | “allows to restore numerous local and systemic microbiota functions” NCT04269850 ↗ |
| Modality | Other / unclassified | “Fecal microbiota transplantation (FMT)” NCT04269850 ↗ |
| Route | Oral | “via po capsules” NCT04203017 ↗ |